Patents by Inventor Andrew A. Raubitschek
Andrew A. Raubitschek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180155449Abstract: The present invention provides recombinant antibody fragments which include a variable domain which has been modified by the addition of a tail sequence to its C-terminal end. The tail sequence comprises a terminal cysteine residue and an amino acid spacer and does not substantially affect the fragment's target-binding affinity. The present invention also provides pharmaceutical compositions comprising the described antibody fragments and a pharmaceutically acceptable ? carrier and methods of delivering an agent to cells of interest in a subject using the fragments as delivery vehicles. The invention further provides compositions comprising the described antibody fragments for the in vitro detection and measurement of target molecules which bind to the fragments and method of determining the presence or amount of such targets in a biological sample by contacting the sample with such compositions.Type: ApplicationFiled: September 18, 2017Publication date: June 7, 2018Inventors: Anna M. Wu, John E. Shively, Andrew A. Raubitschek, Mark A. Sherman, Tove Olafsen
-
Patent number: 9765155Abstract: The present invention provides recombinant antibody fragments which include a variable domain which has been modified by the addition of a tail sequence to its C-terminal end. The tail sequence comprises a terminal cysteine residue and an amino acid spacer and does not substantially affect the fragment's target-binding affinity. The present invention also provides pharmaceutical compositions comprising the described antibody fragments and a pharmaceutically acceptable carrier and methods of delivering an agent to cells of interest in a subject using the fragments as delivery vehicles. The invention further provides compositions comprising the described antibody fragments for the in vitro detection and measurement of target molecules which bind to the fragments and method of determining the presence or amount of such targets in a biological sample by contacting the sample with such compositions.Type: GrantFiled: July 20, 2012Date of Patent: September 19, 2017Assignee: City of HopeInventors: Anna M. Wu, John E. Shively, Andrew A. Raubitschek, Mark A. Sherman, Tove Olafsen
-
Patent number: 9701754Abstract: The present invention provides recombinant antibody fragments which include a variable domain which has been modified by the addition of a tail sequence to its C-terminal end. The tail sequence comprises a terminal cysteine residue and an amino acid spacer and does not substantially affect the fragment's target-binding affinity. The present invention also provides pharmaceutical compositions comprising the described antibody fragments and a pharmaceutically acceptable carrier and methods of delivering an agent to cells of interest in a subject using the fragments as delivery vehicles. The invention further provides compositions comprising the described antibody fragments for the in vitro detection and measurement of target molecules which bind to the fragments and method of determining the presence or amount of such targets in a biological sample by contacting the sample with such compositions.Type: GrantFiled: May 27, 2010Date of Patent: July 11, 2017Assignee: City of HopeInventors: Anna M. Wu, John E. Shively, Andrew A. Raubitschek, Mark A. Sherman, Tove Olafsen
-
Publication number: 20120283418Abstract: The present invention provides recombinant antibody fragments which include a variable domain which has been modified by the addition of a tail sequence to its C-terminal end. The tail sequence comprises a terminal cysteine residue and an amino acid spacer and does not substantially affect the fragment's target-binding affinity. The present invention also provides pharmaceutical compositions comprising the described antibody fragments and a pharmaceutically acceptable carrier and methods of delivering an agent to cells of interest in a subject using the fragments as delivery vehicles. The invention further provides compositions comprising the described antibody fragments for the in vitro detection and measurement of target molecules which bind to the fragments and method of determining the presence or amount of such targets in a biological sample by contacting the sample with such compositions.Type: ApplicationFiled: July 20, 2012Publication date: November 8, 2012Applicant: City of HopeInventors: Anna M. Wu, John E. Shively, Andrew A. Raubitschek, Mark A. Sherman, Tove Olafsen
-
Patent number: 7776330Abstract: Embodiments of the present invention utilize a more efficient CDR grafting technique to generate humanized versions of the T84.66 antibody. The technique used to generate these antibodies utilizes crystallographic structural data to select an immunoglobulin framework having maximum structural overlap with a non-human donor molecule. This technique was used to develop humanized T84.66 antibodies exhibiting in vitro binding affinity and specificity for carcinoembryonic antigen (CEA) nearly identical to that of T84.66 and the ability to specifically target tumors expressing CEA in vivo.Type: GrantFiled: September 25, 2007Date of Patent: August 17, 2010Assignee: City of HopeInventors: Paul J. Yazaki, Mark A. Sherman, John E. Shively, Andrew A. Raubitschek, Anna M. Wu
-
Patent number: 7727525Abstract: The present invention provides anti-CD20 antibody fragments for use as in vivo imaging probes and as therapeutic moieties for the diagnosis and treatment of NHL.Type: GrantFiled: April 27, 2007Date of Patent: June 1, 2010Assignees: City of Hope, The Regents of the University of CaliforniaInventors: Anna M. Wu, Tove Olafsen, Andrew A. Raubitschek
-
Patent number: 7446179Abstract: The present invention relates to a genetically engineered, CD19-specific chimeric T cell receptor and to immune cells expressing the chimeric receptor The present invention also relates to the use of such cells for cellular immunotherapy of CD9+ malignancies and for abrogating any untoward B cell function. The chimeric receptor is a single chain scFvFc:? receptor where scFvFc designates the extracellular domain, scFv designates the VH and VL chains of a single chain monoclonal antibody to CD19, Fc represents at least part of a constant region of an IgG1, and ? represents the intracellular signaling domain of the zeta chain of human CD3. The extracellular domain scFvFc and the intracellular domain ? are linked by a transmembrane domain such as the transmembrane domain of CD4. In one aspect, the chimeric receptor comprises amino acids 23-634 of SEQ I DNO:2.Type: GrantFiled: November 7, 2001Date of Patent: November 4, 2008Assignee: City of HopeInventors: Micahel C. Jensen, Stephen Forman, Andrew Raubitschek
-
Publication number: 20080069816Abstract: Embodiments of the present invention utilize a more efficient CDR grafting technique to generate humanized versions of the T84.66 antibody. The technique used to generate these antibodies utilizes crystallographic structural data to select an immunoglobulin framework having maximum structural overlap with a non-human donor molecule. This technique was used to develop humanized T84.66 antibodies exhibiting in vitro binding affinity and specificity for carcinoembryonic antigen (CEA) nearly identical to that of T84.66 and the ability to specifically target tumors expressing CEA in vivo.Type: ApplicationFiled: September 25, 2007Publication date: March 20, 2008Inventors: Paul Yazaki, Mark Sherman, John Shively, Andrew Raubitschek, Anna Wu
-
Publication number: 20070280882Abstract: The present invention provides anti-CD20 antibody fragments for use as in vivo imaging probes and as therapeutic moieties for the diagnosis and treatment of NHL.Type: ApplicationFiled: April 27, 2007Publication date: December 6, 2007Inventors: Anna Wu, Tove Olafsen, Andrew Raubitschek
-
Patent number: 7273608Abstract: Embodiments of the present invention utilize a more efficient CDR grafting technique to generate humanized versions of the T84.66 antibody. The technique used to generate these antibodies utilizes crystallographic structural data to select an immunoglobulin framework having maximum structural overlap with a non-human donor molecule. This technique was used to develop humanized T84.66 antibodies exhibiting in vitro binding affinity and specificity for carcinoembryonic antigen (CEA) nearly identical to that of T84.66 and the ability to specifically target tumors expressing CEA in vivo.Type: GrantFiled: March 11, 2005Date of Patent: September 25, 2007Assignee: City of HopeInventors: Paul J. Yazaki, Mark A. Sherman, John E. Shively, Andrew A. Raubitschek, Anna M. Wu
-
Publication number: 20050244333Abstract: Embodiments of the present invention utilize a more efficient CDR grafting technique to generate humanized versions of the T84.66 antibody. The technique used to generate these antibodies utilizes crystallographic structural data to select an immunoglobulin framework having maximum structural overlap with a non-human donor molecule. This technique was used to develop humanized T84.66 antibodies exhibiting in vitro binding affinity and specificity for carcinoembryonic antigen (CEA) nearly identical to that of T84.66 and the ability to specifically target tumors expressing CEA in vivo.Type: ApplicationFiled: March 11, 2005Publication date: November 3, 2005Inventors: Paul Yazaki, Mark Sherman, John Shively, Andrew Raubitschek, Anna Wu
-
Publication number: 20040126363Abstract: Genetically engineered, CD19-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CD19, an intracellular signaling domain, and a transmembrane domain. Use of such cells for cellular immunotherapy of CD19+ malignancies and for abrogating any untoward B cell function. In one embodiment, the immune cell is a T cell and the cell surface protein is a single chain scFvFc:&zgr; receptor where scFv designates the VH and VL chains of a single chain monoclonal antibody to CD19, Fc represents at least part of a constant region of an IgG1, and &zgr; represents the intracellular signaling domain of the zeta chain of human CD3. The extracellular domain scFvFc and the intracellular domain &zgr; are linked by a transmembrane domain such as the transmembrane domain of CD4. A method of making a redirected T cell expressing a chimeric T cell receptor by electroporation using naked DNA encoding the receptor.Type: ApplicationFiled: May 7, 2003Publication date: July 1, 2004Inventors: Michael C. Jensen, Stephen Forman, Andrew Raubitschek
-
Patent number: 6410319Abstract: Genetically engineered, CD20-specific redirected T cells expressing a cell surface protein-having an extracellular domain comprising a receptor which is specific for CD20, an intracellular signaling domain, and a transmembrane domain. Use of such cells for cellular immunotherapy of CD20+ malignancies and for abrogating any untoward B cell function. In one embodiment, the cell surface protein is a single chain FvFc:&zgr; receptor where Fv designates the VH and VL chains of a single chain monoclonal antibody to CD20 linked by peptide, Fc represents a hinge-CH2-CH3 region of a human IgG1, and &zgr; represents the intracellular signaling domain of the zeta chain of human CD3. A method of making a redirected T cell expressing a chimeric T cell receptor by electroporation using naked DNA encoding the receptor.Type: GrantFiled: October 20, 1999Date of Patent: June 25, 2002Assignee: City of HopeInventors: Andrew Raubitschek, Anna Wu, Michael C. Jensen
-
Patent number: 5844241Abstract: A system and method determines internal radioactivity and absorbed dose estimates of a patient more accurately and with greater ease. Internal radioactivity is determined by the CAMI (CT scan Assisted Matrix Inversion) system and method which uses uptake information from the gamma camera images and anatomic data from CT (Computerized Tomography) scans. Absorbed dose estimates are obtained by the MAVSK (Monte Carlo Assisted Voxel Source Kernel) system and method which uses a MCNP (Monte Carlo program for electron and photon transport) to simulate a voxel source kernel for .sup.90 Y analogous to a point source function.Type: GrantFiled: July 19, 1996Date of Patent: December 1, 1998Assignee: City of HopeInventors: An Liu, Lawrence E. Williams, Andrew Raubitschek
-
Patent number: 4950598Abstract: Human T-T hybridomas are made by fusing an azaserine-hypoxanthine (AH) sensitive T leukemia cell line, preferably the AH-sensitive mutant of the Jurkat leukemia line identified as J3R7, with normal T cells and culturing the fusion product in a selective AH medium. Stable, interleukin-2 (IL-2)-producing human T-T hybridomas were made by this process.Type: GrantFiled: September 19, 1985Date of Patent: August 21, 1990Assignees: The Board of Trustees of the Leland Stanford Junior University, Cetus CorporationInventors: Edgar G. Engleman, James W. Larrick, Andrew A. Raubitschek, Steven K. Foung
-
Patent number: 4677070Abstract: Anti-Pseudomonas antibodies which bind to exotoxin A from P. aeruginosa are prepared from hybrid cell lines. The antibodies may be of any isotype. These antibodies may be used to treat infections caused by P. aeruginosa.Type: GrantFiled: April 26, 1985Date of Patent: June 30, 1987Assignee: Cetus CorporationInventors: James W. Larrick, Andrew A. Raubitschek
-
Patent number: H1198Abstract: Serotype-specific human anti-Pseudomonas monoclonal antibodies which bind to determinants of the cell wall lipopolysaccharides of P. aeruginosa are prepared from hybrid cell lines. The antibodies may be of any isotype. These antibodies may be used to treat infections caused by P. aeruginosa.Type: GrantFiled: April 26, 1985Date of Patent: June 1, 1993Assignee: Cetus CorporationInventors: James W. Larrick, Andrew A. Raubitschek